DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

Post-LOE

diatrizoate meglumine and diatrizoate sodium

Guerbet

ANDAORAL, RECTALSOLUTION

Approved

Jun 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM (diatrizoate meglumine and diatrizoate sodium) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 2022.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM at Guerbet? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.